Related by context. All words. (Click for frequent words.) 72 antiangiogenic drugs 71 antiangiogenesis 68 antimetabolites 68 mTOR inhibitors 68 antiangiogenic therapy 68 endocrine therapies 67 cisplatin resistant 67 skeletal metastases 67 proliferative disorders 67 KRAS oncogene 67 HER2 positive cancers 67 transgenic rats 66 anti angiogenic agents 66 serous ovarian cancer 66 gefitinib Iressa 66 metastatic neuroendocrine tumors 66 castrate resistant 66 pancreatic lung 66 imatinib Gleevec 66 Gleevec resistant 66 antiandrogen 66 immune modulating 66 nodal metastasis 66 EGFR receptor 65 prostate carcinomas 65 immuno modulatory 65 immunosuppressive therapies 65 radiosensitivity 65 inhibiting tumor 65 metastatic lymph nodes 65 MMP inhibitors 65 antiangiogenic agents 65 androgen ablation 65 flavopiridol 65 isoproterenol 65 HER2 overexpression 65 epithelial tumors 65 benign neoplasms 65 GI bleeds 65 Leucovorin 65 chemoprotective 65 differentiated thyroid 65 ALK inhibitors 65 lymphomas leukemias 65 rituximab Rituxan 65 lenalidomide dexamethasone 65 mutated KRAS 65 squamous cell lung cancer 65 cytotoxic effects 65 p# activation 64 potent antiproliferative 64 tumoral 64 molecular abnormalities 64 chemoresistant 64 pro angiogenic 64 microtubule inhibitor 64 allogeneic HSCT 64 Kinoid 64 Mitomycin C 64 haematopoietic 64 cytostatic 64 autologous SCT 64 metastatic colorectal 64 Interferon beta 64 IGF IR 64 fluoroquinolone resistance 64 neuroendocrine cancers 64 radionuclide therapy 64 anthracycline chemotherapy 64 mutated K ras 64 antitumor effect 64 seminomas 64 vincristine sulfate 64 immunotoxins 64 BCG refractory 64 prostate carcinoma 64 pancreatic prostate 64 malignant ascites 64 MCF7 64 inhibitory effects 64 heparanase 64 Th2 cytokines 64 EGFR tyrosine kinase inhibitors 64 cytolytic 64 thalidomide Thalomid 64 tumor subtypes 64 ERBB2 63 potently inhibited 63 anticancer treatments 63 tumor necrosis 63 Onconase 63 gastric cardia 63 relapsed MM 63 GIST tumors 63 LHRH agonist 63 chemo resistant 63 potent inducer 63 fibrin deposition 63 trastuzumab Herceptin ® 63 transgene expression 63 antineoplastic 63 chlamydial 63 antibody mediated 63 renal carcinoma 63 oncogenic mutations 63 kidney urologic 63 cytotoxics 63 pulmonary metastases 63 thyroid carcinoma 63 mutated KRAS gene 63 haematologic 63 Cytotoxic 63 selectively inhibited 63 corticosteroid therapy 63 Platinol ® cisplatin 63 gastrointestinal stromal tumors GISTs 63 tamoxifen Nolvadex ® 63 squamous cell carcinoma SCC 63 sirtuin activators 63 concurrent chemoradiation 63 malignant pancreatic 63 receptor tyrosine kinase inhibitor 63 CYT# potent vascular disrupting 63 systemic antifungal 63 tumorigenicity 63 refractory prostate cancer 63 TNFa 63 motexafin gadolinium 63 osteosarcomas 63 metastatic lesions 63 IgG4 63 peritoneal carcinomatosis 63 radioimmunotherapy RIT 63 LHRH agonists 63 ischemic tissues 63 malignant lymphomas 63 vasoactive 63 PEGPH# 63 protein kinase inhibitor 63 p# biomarker 63 liver metastasis 63 murine models 63 VEGF inhibitors 62 #I TM# 62 urothelial bladder cancer 62 adjuvant radiotherapy 62 BRCA deficient 62 recombinant erythropoietin 62 PARP inhibition 62 cisplatin chemotherapy 62 lymphoid cells 62 diagnostic biomarker 62 EGFR HER2 62 Removab 62 erlotinib Tarceva 62 cephalosporin antibiotics 62 pyrimethamine 62 androgen receptor AR 62 cytoreduction 62 dasatinib Sprycel 62 silibinin 62 papillary renal cell carcinoma 62 cardiotoxic 62 baseline LDH 62 transarterial 62 neoplastic cells 62 alkylating agent 62 conventional chemotherapies 62 lung metastasis 62 Immunohistochemical staining 62 Bleomycin 62 radiolabeled antibodies 62 albumin bound paclitaxel 62 recurrent metastatic 62 estramustine 62 HER2 expression 62 thrombocytopenic 62 antiangiogenic agent 62 hCG Beta 62 adjuvant cisplatin 62 paclitaxel Taxol 62 Leukemias 62 factor TNF 62 Modrenal 62 inflammatory cytokine 62 hematopoietic cancers 62 hepatorenal syndrome 62 lytic 62 Xanafide 62 tumor histology 62 antibiotics ciprofloxacin 62 Nicole Onetto MD 62 Immunosuppressive drugs 62 HuLuc# 62 effector function 62 investigational therapies 62 ERK activation 62 biomarker identification 62 antiproliferative effects 62 hormone gastrin 62 bleomycin 62 CYP#D# inhibitor 62 CDK4 62 inhibit viral replication 62 GBM tumors 62 chemotherapeutic drug 62 human chorionic gonadotropin hCG 62 VEGF expression 62 hormone receptor status 62 Darinaparsin 62 Pertuzumab 62 hepatoma 62 anti angiogenic drugs 62 CD# upregulation 62 EGFR mutant 62 histological subtype 62 humoral responses 62 nonnucleoside reverse transcriptase inhibitors 62 macrolide antibiotics 62 GISTs 62 Vidaza azacitidine 62 colorectal tumor 62 trastuzumab Herceptin 62 Fibroblast 62 HER2 positive breast 62 cytotoxicity assays 62 pegfilgrastim 62 Panzem 62 mammary cancers 62 Glioblastoma multiforme GBM 62 Enzastaurin 62 FOLFIRINOX 62 M2 subunit 62 infused intravenously 62 neuroinflammatory 62 androgen receptor signaling 62 hypoxia induced 62 rifamycins 62 Clusterin 62 phosphate binding 62 mucinous 62 cefotaxime 62 metastatic gastric 62 MGd 62 therapeutic regimens 62 androgen hormone 62 cytotoxins 62 FLT3 62 Squamous 62 localized prostate 62 treating neuropathic pain 62 telomerase inhibition 62 ERK signaling 62 parthenolide 62 colony stimulating factors 62 BRAF inhibitors 62 intestinal mucosal 62 KRAS status 61 nucleoside analogs 61 CXCR4 receptor 61 lymphoma subtypes 61 PD# [005] 61 preoperative chemotherapy 61 CEACAM1 61 inhibit EGFR 61 follicular lymphoma FL 61 surgically resectable 61 BRAF protein 61 adjuvant therapies 61 bladder ovarian 61 oesophageal adenocarcinoma 61 posttranslational modification 61 suppresses tumor 61 PPARg 61 mTOR signaling 61 Gleevec Glivec 61 BMPR2 61 mesenchymal cell 61 antiresorptive 61 chemopreventive agent 61 subcutaneous immunoglobulin 61 antihormonal 61 adrenal hormone 61 PLX MS 61 PROCHYMAL 61 gastric carcinoma 61 GnRH agonists 61 alpha fetoprotein AFP 61 colorectal carcinomas 61 gastric adenocarcinoma 61 pharmacokinetic interactions 61 HbF 61 radiotherapeutic 61 p# Shc 61 chimeric monoclonal antibody 61 ovarian pancreatic 61 necrotic core 61 Gliadel Wafer 61 survivin expression 61 biliary tract cancer 61 IL 1ß 61 Anthracycline 61 chemosensitivity 61 intradermal injection 61 neovascularisation 61 antiplatelet therapies 61 colorectal adenocarcinoma 61 OMP #M# 61 breast carcinoma 61 griseofulvin 61 KRAS mutations occur 61 immunosuppressive regimens 61 Fibroblast Growth Factor Receptor 61 EGFR protein 61 Thalomid ® 61 bronchogenic carcinoma 61 MTT assay 61 EGFR pathway 61 DNA methyltransferases 61 tubulin binding 61 metastatic melanomas 61 etoposide 61 redox active 61 salinomycin 61 ixabepilone 61 cervical lymph nodes 61 nonproliferative 61 virotherapy 61 urothelial carcinoma 61 hematopoietic progenitor cells 61 induced cytotoxicity 61 carcinoids 61 Protein Kinase C 61 LTB4 61 chemotherapeutic regimen 61 JAK2 enzyme 61 immune suppressing 61 prophylactic cranial irradiation 61 pancreatic adenocarcinoma 61 androgen suppression 61 mTOR signaling pathway 61 conventional DMARDs 61 pretreatment serum 61 TMP SMX 61 #F FDG 61 vivo potency 61 glioma cells 61 endometrial hyperplasia 61 upregulating 61 inhibit replication 61 viral titers 61 plasminogen activators 61 lung carcinomas 61 Velcade bortezomib 61 Radiofrequency ablation 61 nonmetastatic 61 SIR Spheres 61 osteoblastic 61 zoledronate 61 mononuclear cell 61 beta interferons 61 lactate dehydrogenase 61 telomerase inhibitor 61 Oxaliplatin 61 pentamidine 61 Soy isoflavones 61 cytoprotective 61 intravenous bisphosphonates 61 CD# expressing 61 microglial activation 61 selective modulator 61 EGF receptors 61 apoptotic pathways 61 lesional 61 bone morphogenetic proteins 61 fusion enhancers 61 busulfan 61 nanomolar 61 antimitotic 61 gemcitabine carboplatin 61 fumagillin nanoparticles 61 prednisone prednisolone 61 LHRH receptor positive 61 refractory Hodgkin 61 CsA 61 tumor hypoxia 61 curability 61 Beta catenin pathway 61 hypervascular 61 esterases 61 RRM1 61 IFN beta 61 neoadjuvant therapy 61 radiotherapy RT 61 antiangiogenic 61 Xelox 61 Aplidin 61 bronchial epithelial cells 61 TNF alpha antagonist 61 colorectal liver metastases 61 tissue fibrosis 61 Cloretazine R 61 myelomas 61 Madin Darby canine 61 invasive lobular 61 adalimumab Humira 61 radiolabeled TM# 61 HGPIN 61 humanized monoclonal antibodies 61 Her2 positive 61 intracranial hemorrhage ICH 61 Neulasta ® 61 FVIIa 61 GnRH analogue 61 tyrosine kinase inhibitors TKIs 61 NSCLC tumors 61 cranial irradiation 61 proteasome inhibitor 61 sarcomatoid 61 LHRH analogues 61 immunofluorescence microscopy 60 OGG1 60 multitargeted 60 potentially hepatotoxic 60 BRCA1 BRCA2 60 benign uterine 60 Protease inhibitors 60 miRs 60 distal colon 60 vestibular schwannomas 60 trophoblast cells 60 complete cytogenetic response 60 pediatric acute lymphoblastic 60 Cloretazine 60 T#I [002] 60 highly vascularized 60 inducible nitric oxide synthase 60 p# mutations 60 mitochondrial toxicity 60 PI3K/mTOR 60 CCL# 60 precursor lesions 60 mTOR inhibition 60 Basal cell 60 K ras mutations 60 EGFR mutation positive 60 NeoLipid TM 60 breast cancer subtypes 60 fibrinolytic 60 Taxol ® 60 DCVax R 60 endostatin 60 macrolide resistance 60 Immunohistochemical analysis 60 intratumoral 60 mycophenolate 60 androgen dependent 60 NF kB pathway 60 granulosa cell 60 osteoclast activity 60 xenograft models 60 gene amplification 60 antitumor immune 60 synovial fibroblasts 60 Estrogen receptor positive 60 flutamide 60 SETDB1 60 Crizotinib 60 amyloid plaque formation 60 percutaneous biopsy 60 unresectable tumors 60 indolent lymphomas 60 HepDirect technology 60 circulating endothelial cells 60 leukaemias 60 FGFR4 60 pancreatic carcinoma 60 GBMs 60 HER2 receptor 60 CD4 + T lymphocytes 60 N Myc 60 KRAS mutated 60 leiomyomas 60 Papillary 60 vWF 60 anaplastic 60 adenomatous 60 taxane chemotherapy 60 Pemetrexed 60 Microarray analysis 60 Vidaza ® 60 isoenzyme 60 bortezomib Velcade 60 malignant growths 60 Amino acid 60 vitamin D analogs 60 protein kinase inhibitors 60 inhibits VEGF 60 rHuEPO 60 PIK3CA 60 colon carcinoma 60 adriamycin 60 TNF α 60 prostate cancer CaP 60 thrombo embolic 60 neurotrophic 60 hematologic abnormalities 60 FUSILEV enhances 60 metachronous 60 chemotherapeutic drugs 60 Gefitinib 60 adverse cytogenetics 60 beta1 integrin 60 MYLOTARG 60 anti androgens 60 uPA 60 debulking surgery 60 invasive ductal 60 gastrointestinal stromal tumors GIST 60 melanoma tumors 60 Akt activation 60 Erlotinib 60 interferon ribavirin 60 lung pancreatic 60 intestinal polyps 60 neoplastic lesions 60 potent suppressor 60 anal lesions 60 multiorgan 60 sargramostim 60 MAGE A3 ASCI 60 SSc 60 Vandetanib 60 antibody cytokine 60 recurrent glioblastoma multiforme GBM 60 PI3K AKT 60 SERMs 60 leukemic cell 60 lipid synthesis 60 Flu Cy 60 refractory gastrointestinal stromal 60 colorectal carcinoma 60 underwent surgical resection 60 autologous hematopoietic stem cell 60 alkylating 60 clonal expansion 60 GSK3B 60 CHOP chemotherapy 60 surgical debulking 60 benzimidazole 60 antitumour 60 small molecule tyrosine 60 Anaplastic 60 cisplatin gemcitabine 60 HER2 amplification 60 tumor nodules 60 pancreatic islet cell 60 efaproxiral 60 FGFs 60 Avastin Tarceva 60 neutrophil counts 60 nicotinic acetylcholine receptor 60 antiandrogens 60 receptor blocker 60 Sutent sunitinib 60 fluconazole resistant 60 mutated p# 60 eIF 4E 60 radiocontrast 60 biologic therapeutics 60 Triapine R 60 androgen hormones 60 antisense molecules 60 mediated inhibition 60 CYP#A# enzyme 60 JAK#/JAK# 60 demonstrated antitumor activity 60 KRAS mutation 60 lymphoid organs 60 ERalpha 60 anti CD3 60 Smac mimetic 60 IgG1 60 gene rearrangements 60 alefacept 60 PSMA ADC 60 Butyrate 60 P. acnes 60 tubulin inhibitor 60 HepG2 cells 60 direct thrombin inhibitors 60 Src kinase 60 differential gene expression 60 micrometastasis 60 Anti angiogenic 60 G#DT 60 Adjuvant chemotherapy 60 uricase 60 oxidative metabolism 60 pamidronate 60 leucocytes 60 hepatocellular carcinomas 60 Trastuzumab 60 ERK1 2 60 ovarian carcinoma 60 NMDA antagonists 60 immunomodulation 60 KIT mutations 60 enterococcal 60 extramedullary 60 circulating endothelial progenitor cells 60 monogenic 60 peptidic 60 synthetic analogues 60 nonmelanoma skin cancers 60 AChE inhibitors 60 histologies 60 phenotypic expression 60 chemotherapeutics 60 efficacy evaluable 60 Chlamydia trachomatis infection 60 uterine tumors 60 Anticalins ® 60 EGFRIs 60 pegylated liposomal doxorubicin 60 urothelial cancer 60 antiepileptic drugs AEDs 60 completely resected 60 antiapoptotic 60 subcellular compartments 60 ELISPOT assay 60 proteolytic cleavage 60 systemic toxicity 60 seminoma 60 deacetylation 60 nucleotide analogs 60 ADAMTS# 60 genomic alterations 60 hormonally responsive 60 erlotinib Tarceva ® 60 paragangliomas 60 alveolar epithelial cells 60 antiemetics 60 myelofibrosis polycythemia vera 60 Prolastin A1PI 59 medically inoperable 59 sCD# 59 Tumor Response 59 EGFR inhibitors 59 Epstein Barr Virus EBV 59 prostaglandin analogues 59 Medullary thyroid cancer 59 monoclonal antibody therapies 59 compound AEZS 59 BEACOPP 59 antiparasitic drugs 59 PPAR gamma agonists 59 hypervascular tumors 59 oncoproteins 59 E. faecalis 59 cyclophilin D 59 Antitumor 59 Roche Herceptin 59 PKC inhibitors 59 adrenocortical 59 anastrazole 59 lymphocytic 59 indinavir 59 ganciclovir 59 renal cell carcinomas 59 orthotopic 59 glatiramer 59 fibrate drugs 59 MEK inhibitors 59 promoter hypermethylation 59 gastroesophageal junction 59 VEGF receptor 59 MAPK pathway 59 B7 H3 59 Gastrointestinal Stromal Tumors 59 pancreatic islet 59 potent anti angiogenic 59 anticonvulsant medications 59 Tigecycline 59 PDGF BB 59 elevated LDH 59 patients undergoing chemotherapy 59 HIF 1α 59 somatostatin receptor 59 PI3K Akt 59 adipose tissue fat 59 Evoltra ® 59 receptor inhibitors 59 adeno associated viruses 59 chemotherapeutic 59 immunomodulatory therapies 59 AMPK activators 59 apoptosis inducing 59 Rituxan rituximab 59 etanercept Enbrel 59 metaplasia 59 recurrent glioblastoma multiforme 59 intravenous cyclophosphamide 59 detecting precancerous 59 pCR 59 immune modulatory 59 histologic subtype 59 ESBA# 59 Neupogen ® 59 synovial cells 59 CBLC# 59 antisense inhibitors 59 plasmacytoid 59 myeloablative 59 phosphorylated proteins 59 thymidine kinase 59 Leydig cell 59 GHRH 59 fulminant hepatic failure 59 relapsed ovarian cancer 59 PDGF receptor 59 Fluorouracil 59 unconjugated 59 immunodeficiency disorders 59 invasive carcinoma 59 Taxanes 59 taxane refractory 59 inhibited tumor 59 microRNA expression 59 germline mutations 59 Hematopoietic 59 metastatic bladder 59 nephrotoxic 59 receptor inhibitor 59 chemopreventive agents 59 excitotoxic 59 osteogenic 59 erythropoietic 59 antidepressants SSRIs 59 secretory pathway 59 hematological indications 59 median survivals 59 somatostatin analogs 59 mda 7 59 DNA intercalator 59 Dacogen decitabine 59 piperacillin tazobactam 59 verteporfin 59 H. pylori eradication 59 #T# L1 59 anaplastic thyroid carcinoma 59 hormonally sensitive 59 immune suppressive 59 HDACi 59 clinically evaluable 59 azelaic acid 59 L asparaginase 59 potently inhibit 59 caspofungin 59 imexon 59 inotropic 59 Antibacterials 59 ALK mutations 59 histone deacetylase inhibitor 59 histone deacetylase HDAC 59 antitumor efficacy 59 TroVax ® 59 potent cytotoxic 59 metastatic malignant 59 CFTR inhibitors 59 stem cell transplantations 59 Sudhir Agrawal D.Phil 59 adipogenic 59 therapeutically relevant 59 lumiliximab 59 mediated inflammatory 59 antisense compounds 59 oncogenic transformation 59 Bacillus Calmette Guerin BCG 59 TNFalpha 59 PhG alpha 1 59 Heavy menstrual bleeding 59 corticosteroid dexamethasone 59 coexpression 59 EBV infection 59 pancreatic ductal 59 Temsirolimus 59 effector cells 59 Arranon 59 Fludarabine 59 CA4P 59 APTIVUS R 59 vorinostat 59 uric acid lowering 59 Src inhibitors 59 thromboxane A2 59 fulvestrant 59 colorectal adenoma 59 basiliximab 59 pDCs 59 leflunomide 59 isotypes 59 somatostatin analogues 59 galiximab 59 hypericin 59 tigecycline 59 carcinoid tumors 59 amphotericin 59 tumor regressions 59 anti tumoral 59 Bcr Abl mutations 59 genital herpes infections 59 tiuxetan 59 eribulin mesylate 59 TNFα 59 IGFBP2 59 embryonal 59 macrophage cells 59 proinflammatory mediators 59 integrin receptors 59 BRAF gene 59 nonalcoholic steatohepatitis NASH 59 extracellular dopamine 59 intra tumoral 59 RAS mutations 59 intimal hyperplasia 59 nonsmall cell lung cancer 59 ionotropic 59 CellCept mycophenolate mofetil 59 premalignant 59 octreotide LAR 59 spontaneously regress 59 thrombotic complications 59 molecular biomarkers 59 CD# expression [001] 59 Valproic acid 59 beta1 59 IOP lowering 59 monocyte macrophage 59 Intravenous immunoglobulin 59 premalignant lesions 59 cancerdefine 59 Gleevec imatinib mesylate 59 paclitaxel poliglumex 59 PC3 cells 59 tracer uptake 59 locoregional recurrence 59 Alequel 59 doxorubicin Adriamycin 59 quasispecies 59 CD8 + cytotoxic 59 induce regression 59 lymphoid malignancies 59 SUVmax 59 Taxol paclitaxel 59 rhGH 59 C#BL 6 mice 59 Pegylated Interferon 59 differentiating squamous 59 ERK phosphorylation 59 eicosanoid 59 Camptosar ® 59 relapsed ALL 59 vinca alkaloids 59 locoregional disease 59 acetylcholine receptor 59 gene deletions 59 capsular polysaccharide 59 Treg cell 59 DFMO 59 thromboembolic disease 59 cytotoxic agents 59 immuno suppressants 59 anti angiogenic therapy 59 gemifloxacin 59 murine model 59 S. maltophilia 59 metastatic prostate 59 chemotherapeutic regimens 59 endothelial activation 59 lung fibrosis 59 ENMD # 59 antitumoral 59 neuro protective 59 ABCB1 gene 59 azacytidine 59 intraductal 59 carcinoid 59 prostate adenocarcinoma 59 ara C 59 ABL1 59 oral clodronate 59 chromosomal mutations 59 vinca alkaloid 59 TTF therapy 59 nonvaccine 59 skeletal myoblasts 59 deacetylase inhibitors 59 Fingolimod 59 Myelodysplastic syndromes MDS 59 cytological 59 cediranib 59 prostanoid 59 Epirubicin 59 induced sputum 59 TET2 59 liposome encapsulated 59 histone deacetylase HDAC inhibitors 59 Chronic pancreatitis 59 potent anticancer 59 Radiofrequency Ablation RFA 59 protease inhibitors PIs 59 Immunotherapeutic 59 factor PlGF 59 neuroregenerative 59 adipose derived regenerative 59 CLL cells 59 candidemia 59 malignant neoplasm 59 eIF4E 59 oligodendrogliomas 59 esophageal tumors 59 nucleoside analogues 59 Novartis Gleevec 59 complement inhibitor eculizumab 59 insulin glulisine 59 mupirocin 59 renal cysts 59 protein tyrosine phosphatase 1B 59 FOLFOX chemotherapy 59 granulocyte 59 Li Fraumeni 59 trans splicing 59 humanised antibody 59 Glioblastoma Multiforme GBM 59 antiinflammatory 59 insertional mutagenesis 59 antihormonal therapy 59 TGF alpha 59 hyperacute 59 pharmacologic intervention 59 chemotherapeutic treatments 59 thetreatment 59 liposomes containing 59 paclitaxel cisplatin 59 Olmesartan 59 breast endometrial 59 neuroblastomas 59 Squamous cell 59 induce remission 59 anti angiogenic therapies 59 EGFR tyrosine kinase inhibitor 59 malignant phenotype 59 BCR ABL mutations 59 ischemia induced 59 Pseudomonas aeruginosa infections 59 transarterial chemoembolization 59 vascularisation 59 radiofrequency ablation RFA 59 uremic 59 GCase 59 phototoxicity 59 therapeutic radiopharmaceuticals 59 cardiometabolic disorders 59 metabolomic profiles 59 hypothalamic pituitary 58 neurosteroid 58 Tissue Factor 58 immunosuppressives 58 SPECT CT imaging 58 tryptase 58 Hypotension 58 Irinotecan 58 hormone refractory 58 EGF receptor 58 Apo2L 58 antiestrogen 58 interferon beta therapy 58 interferon IFN 58 Surgical excision 58 OHR/AVR# 58 KRAS mutant 58 hematopoietic cells 58 extensively metabolized 58 lobular carcinomas 58 degranulation 58 prokinetic 58 radiolabeled 58 sodium stibogluconate 58 vasopressor 58 bovine thrombin 58 microwave hyperthermia 58 lipid lowering therapies 58 K ras gene 58 tumors GIST 58 superantigens 58 alkylating agents 58 preferentially bind 58 rituximab Rituxan ®